Paul Nathan, PhD
Articles
Newly Approved Tebentafusp Requires Up-Front Active Toxicity Management in Melanoma
February 14, 2022
Video
Tebentafusp, the first FDA-approved treatment option for patients with unresectable or metastatic uveal melanoma, may cause mild cytokine release syndrome, an expert explains.